usMIMA has developed the MOWOOT, a Non-pharmacological, Non-invasive solution to constipation without side-effects in form of a device that emulates the massage techniques of professional therapists, administered by an actuator matrix and controlled by a central software that permits monitoring and adjustment of the massage delivered.

1. usMIMA S.L. - CIF. B66400409 - Calle Llacuna 162, 08018, Barcelona - Tel. 93 510 66 53
Contact.
Markus Wilhelms - CEO & Co-founder - markus@usmima.com / markus@mowoot.com
Executive Summary of usMIMA S.L.
2016, Barcelona, Spain

2. 2
Confidential
THE PROBLEM
OUR PRODUCT
usMIMA has developed the MOWOOT, a Non-pharmacological, Non-invasive
solution to constipation without side-effects in form of a device that emulates the
massage techniques of professional therapists, administered by an actuator matrix
and controlled by a central software that permits monitoring and adjustment of the
massage delivered.
The MOWOOT-v1.0 consists of a lightweight belt based on pneumatic technology
that is capable of stimulating the colon and moving the feces, reaching up to 7 cm
deep in the abdomen. MOWOOT-v1.0 is controlled by an external desktop device
that generates and controls the massage algorithms.
Due to failure of fecal propulsion Neurogenic Bowel Patients (SCI, Parkinson, Multiple
Sclerosis, etc.) are chronically constipated, leading to difficult and painful evacuation,
fecal impaction, fecal incontinence and a big negative impact on their quality of life.
Up to 15% of the general population is also diagnosed with chronic or re-occurring
constipation.
Current solutions are either pharmacological, like laxatives, or invasive, like enemas
and intestinal pacemakers.
Figure 1: The MOWOOT-v1.0 (left); detail of inside of the belt with inflating actuator (right)

3. 3
Confidential
THE SOLUTION
scientific publications show the positive effects of abdominal massage for the
intestinal transit and a as remedy for chronic constipation (Emly 2001; Lamas et
al. 2009; 2010; 2011; 2012; McClurg 2011).
In a clinical study our pre-prototype doubled the defecation frequency of idiopathic &
neurogenic patients. (Figure 3)
Defecation Frequency doubles!
Figure 3: Pre-prototype clinical tests show doubling of
defecation frequency of patients (idiopathic & neurogenic
patients).
THE OPPORTUNITY
Patients with chronic or re-occurring constipation are looking for a non-pharmaceutical,
non-invasive solution, as the existing solutions have side-effects, lose their efficacy with
time and bare an additional health risk for the user. Furthermore the current solutions
easily add up to over 700€ a year for the chronic patient. (Figure 2)
Price[€/Year]
Side Effects
under 500€
SARS
>35.000€
Enemas
2.300€/year
Laxatives
700€/year
Figure 2: Opportunity Gap

4. 4
Confidential
REGULATORY ASPECTS
Our device passed all necessary regulatory tests without problems and the CE
certification for class IIa medical devices have been obtained from prestigious notified
body BSI Group.
HOW MANY PEOPLE SUFFER FROM CHRONIC CONSTIPATION?
In a startup phase we want to focus on the people with Neurogenic Bowel Disease
that need this solution to constipation the most: People with spinal cord injury, multiple
sclerosis or Parkinson Disease. Starting on the national level (Target Market), we want
to expand all over Europe and United States, and finally also reach the general
population that suffers from chronic constipation. In Europe & the United States alone
over 150 million people are diagnosed with chronic constipation.
300.000
People
2.5 mio
People
150 mio
People
Spain US & EU US & EU
Constipated people in
Spinal Cord Injury, Parkinson,
Multiple Sclerosi
Constipated people in
Spinal Cord Injury, Parkinson,
Multiple Sclerosi
Constipated people in
General Population
Figure 4: Segmentation of patients suffering from chronic constipation
MD 649373

5. 5
Confidential
THE FOUNDER TEAM
The multidisciplinary team of usMIMA consists of 4 founding members: Markus
Wilhelms(CEO),PhD in Molecular Microbiology; Immaculada Herrero Fresneda(CSO/
COO), PhD in Biomedical Sciences; Marc Benet Pozo(CCO), Technical Engineer
in Industrial Design & M.Sc. in Design Engineering and Àngel Calzada Defez
(CTO),Telecommunications Engineer specialized in software engineering.
usMIMA emerged out of MOEBIO dHEALTH program by Biocat and is winner of
the latest edition of BioEmprendedorXXI competition as “best health/bio startup of
Catalunya” (Caixa Banc).
For more information about our product see www.mowoot.com
Figure 5: The usMIMA Team, Marc, Àngel, Markus & Immaculada (From left)